>>Signaling Pathways>> Metabolism>> 5-alpha Reductase>>Finasteride

Finasteride (Synonyms: MK-906)

Catalog No.GC16248

Finasteride(MK-906)는 유형 II 5α-환원효소에 대한 IC50이 4.2nM인 강력하고 경쟁력 있는 5α-환원효소 억제제입니다. Finasteride는 type I 효소보다 type II 5α-reductase 효소에 대해 약 100배 더 큰 친화력을 가지고 있습니다. 피나스테리드는 양성 전립선 비대증(BPH) 및 안드로겐 탈모증의 연구에 사용할 수 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

Finasteride Chemical Structure

Cas No.: 98319-26-7

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$39.00
재고 있음
100mg
US$39.00
재고 있음
200mg
US$58.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Finasteride is an orally active testosterone 5-alpha-reductase inhibitor (Ki= 10 nM). Target: 5-alpha ReductaseApproved: 1992Finasteride, a synthetic 4-azasteroid antiandrogen compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). Finasteride is used in the treatment of prostate cancer, benign prostatic hyperplasia, and androgenetic alopecia (male pattern baldness). In benign prostatic hyperplasia, finasteride inhibits 5alpha-reductase activity in epithelium for Ki of 10 nM, significantly lower than in stroma (Ki = 33nM) [1].

References:
[1]. Weisser, H. and M. Krieg, In vitro inhibition of androstenedione 5alpha-reduction by finasteride in epithelium and stroma of human benign prostatic hyperplasia. J Steroid Biochem Mol Biol, 1998. 67(1): p. 49-55.

리뷰

Review for Finasteride

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Finasteride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.